Delivery Order SPE2DB20D3303-SPE2DB25FA3RG
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,728.17 to AmerisourceBergen Drug Corp for the supply of Venclexta 100 mg tablets (120 count) on August 21, 2025, with an ultimate completion date of September 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of VENCLEXTA 100 mg tablets (120 count), valued at $9,728.17. This firm fixed-price, competitively awarded delivery order is expected to be completed by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting the company's demonstrated...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,728.17 to AmerisourceBergen Drug Corp for 120 tablets of Venclexta 100 mg on September 10, 2025, with completion targeted for October 1, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $1 billion through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Venclexta 100 mg tablets (120-count units) under a firm fixed-price arrangement. The contract, valued at $9,728.17, is scheduled for completion by August 11, 2025, and was awarded on July 21, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance. This delivery order represents a competitively awarded, non-set-aside contract...
- The Defense Logistics Agency awarded a $2,289.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Venclexta 100 mg tablets (28-count unit dosage). This non-set-aside competitive award is scheduled for completion by September 30, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Venclexta 100 mg tablets (120-count units) under a firm fixed-price contract valued at $9.7K. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9M through December 2026. The award was made through open competition with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Venclexta 100 mg tablets in a quantity of 120 units, with a ceiling value of $9,728.17. This is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and represents a competitive award with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Venclexta 100 mg tablets in quantities of 120 units. This firm fixed price delivery order, valued at $58,369.02, represents a non-competitive, non-set-aside award and is scheduled for completion by August 14, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Venclexta 100 mg tablets in a quantity of 28 units, with a ceiling value of $2,289.70. This is a firm fixed-price delivery order with no set-aside designation, issued competitively. The contract is expected to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Venclexta 50 mg tablet unit dose packages (quantity 7). This non-set-aside, competitively awarded contract is valued at $1,743.06 with a firm fixed price and is scheduled for completion by September 4, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3RGDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,579.40 to AmerisourceBergen Drug Corp for the supply of Venclexta 100 mg tablets (28-count units) on September 12, 2025. This firm fixed-price, non-set-aside delivery order is scheduled for completion by October 3, 2025, with performance taking place at the contractor's Conshohocken, Pennsylvania location. The award represents a routine pharmaceutical procurement supporting federal medical supply chain requirements, likely serving military healthcare systems and veteran health programs under the DLA's medical supply operations. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's selection for this award and its prime vendor status reflect its demonstrated capability to meet competitive federal procurement standards and support the Defense Health Agency's pharmaceutical distribution requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 9/12/25 |